ProCell Surgical Inc.

ProCell Surgical Inc. manufactures the ProCell® system, the first and only automated medical device designed to recover blood from surgical sponges for intraoperative autotransfusion (IAT). The system automates the collection and processing of blood-saturated sponges during surgery, enabling reinfusion of the patient's own blood and reducing the need for allogeneic transfusions. The device is positioned as a blood conservation technology that optimizes perioperative hemostasis management. Key claimed benefits include elimination of blood splatter, reduced plasma-free hemoglobin compared to manual methods (hand-wringing), decreased LDH levels, and improved OR workflow ergonomics and safety. The ProCell system serves general surgery, orthopedic, cardiac, and trauma surgical specialties where significant intraoperative blood loss occurs. The company holds two US patents (9,199,009 and 10,039,867) and pending patents covering the automated sponge blood recovery technology. ProCell operates in the blood management and surgical hemostasis segment, targeting hospital operating rooms and surgical centers seeking to reduce transfusion rates, improve patient safety, and achieve cost savings through autologous blood recovery.